From Investing.com:

Medivir AB, a biopharmaceutical company specializing in cancer drug development, completed a rights issue on November 7, 2023, and a directed share issue to Hallberg Management AB on January 22, 2024, resulting in an increase of 56,211,817 ordinary shares. As of the last trading day of January, the company has a total of 112,917,968 shares, comprising 112,053,218 ordinary shares and 864,750 class C-shares, with a total of 112,139,693 votes.

Medivir’s focus is on developing innovative drugs for cancer treatment, specifically in areas with high unmet medical needs. Their current focus is on fostrox, a pro-drug aimed at treating liver cancer with minimal side effects. The company pursues drug development independently or in partnership with collaborators and partners.

Medivir’s share is listed on the Nasdaq Stockholm Small Cap list, and this information was released for publication at the time stated by the company’s news distributor. The announcement of the share and vote increase is based on a press release from Medivir.

The original article was generated with the support of AI and reviewed by an editor. For more information, see our T&C.



Read more: Medivir reports share and vote count increase after issues By Investing.com